6 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
and CKD EMPA-REG ... outcomes in HFrEF on GDMT ... outcomes in HFrEF on GDMT ... visualabstract #table ... #CVD #CKD
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
hypoglycaemic agents #Diabetes ... #Diabetic #Medications ... Renal #Impairment #CKD ... #Table #GFR #Hypoglycemics
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... -4 inhibitors SGLT2 ... Improved outcomes in CKD ... EricsMedicalLectures/featured #diabetes
Patient factors influencing the selection Of glucose-lowering drugs Other than SGLT2i and metformin in T2D and
metformin in T2D and CKD ... sulfonylurea; T2D. type 2 diabetes ... type 2 diabetes; ... , #KDIGO2020 #CKD ... #Diabetes Management
Characteristics of Common Lipid Disorders
Polygenic hypercholesterolemia
Atherogenic dyslipidemia
 • Frequently accompanied by central obesity or diabetes
Familial hypercholesterolemia,
central obesity or diabetes ... history of premature CHD ... Family history of CHD ... Family history, CHD ... diseases #comparison #table
Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
angiotensin-receptor blocker; CAD ... resynchronization therapy; DM, diabetes ... ejection fraction; GDMT